Datavault AI signs non-binding deal for 19.9% stake in DataMEDS AI in exchange for expanded technology license
DVLT•DVLT•DVLT•DVLT•Datavault AI signed a non-binding letter of intent to acquire a 19.9% fully diluted stake in DataMEDS in exchange for an expanded technology license. CEO Nathaniel Bradley expects the deal to close in the fourth quarter of 2026, subject to due diligence and definitive agreements.
Datavault AI signed a non-binding letter of intent to acquire a 19.9% stake in DataMEDS on a fully diluted basis in exchange for an expanded technology license. The licensor would retain the underlying intellectual property, while DataMEDS would cover commercialization costs; the proposed arrangement offers potential royalty revenue to the licensor.
Completion remains subject to due diligence, definitive agreements and customary closing conditions. CEO Nathaniel Bradley expects a fourth-quarter 2026 closing.
